Kura Oncology Advances Darlifarnib as Combination Backbone Platform Across KRAS-Mutant Cancers

Phase 1a response rates of 67% in pancreatic cancer and 50% in NSCLC position Kura Oncology's darlifarnib as a potential multi-indication combination backbone, with a platform trial design that will require CMC teams and supply chain planners to anticipate accelerated scale-up across several concurrent development arms.

Data presented at the 2026 ASCO Annual Meeting from the FIT-001 study evaluated darlifarnib plus adagrasib in 26 response-evaluable patients with KRAS G12C-mutated pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). Tumor shrinkage was observed in 77% of patients overall and in 94% of KRAS inhibitor-naïve patients. Confirmed objective response rates reached 67% in PDAC, 50% in NSCLC, and 29% in KRAS inhibitor-naïve CRC, with clinical activity also recorded in patients previously treated with KRAS inhibitors.

These results represent the third clinical validation of Kura's farnesyl transferase inhibitor (FTI) combination strategy, following earlier signals in renal cell carcinoma and PIK3CA-mutated head and neck cancer. Preclinical translational data indicate darlifarnib inhibits RHEB farnesylation and sustains suppression of mTORC1 signaling, a pathway associated with adaptive resistance to KRAS inhibition, with anti-tumor activity demonstrated across mutant-selective, pan-KRAS, and RAS(ON) multi-selective inhibitor classes.

For manufacturing and regulatory teams, the platform trial structure introduces compounding complexity. Rather than a single IND-defined program, a multi-arm platform study generates overlapping process validation timelines, separate comparability packages for each combination partner, and potentially divergent 21 CFR Part 211 documentation requirements per arm. Supply forecasting for an FTI-class compound across simultaneous indications and combination partners demands early engagement between clinical operations and CMC leads to avoid material shortfalls at Phase 1b expansion.

Kura has confirmed the first planned platform combination, darlifarnib plus daraxonrasib in KRAS-mutant pancreatic cancer, is expected to enter Phase 1a evaluation in early 2027, providing a near-term milestone against which manufacturing readiness and regulatory submission timelines can be benchmarked.

Source: Kura Oncology via GlobeNewswire, June 3, 2026. Virtual investor event held same day at 12:15 p.m. PT / 3:15 p.m. ET.